Zoetis Inc. (ETR:ZOE)
Germany · Delayed Price · Currency is EUR | Market Cap | 55.76B |
| Revenue (ttm) | 7.99B |
| Net Income (ttm) | 2.22B |
| Shares Out | n/a |
| EPS (ttm) | 4.95 |
| PE Ratio | 25.07 |
| Forward PE | 22.32 |
| Dividend | 1.75 (1.39%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 441 |
| Average Volume | 259 |
| Open | 126.78 |
| Previous Close | 126.32 |
| Day's Range | 125.94 - 128.16 |
| 52-Week Range | 119.54 - 176.26 |
| Beta | 0.90 |
| RSI | 58.83 |
| Earnings Date | Nov 4, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Full Company ProfileFinancial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis Stock: Outlook Remains Muted
Zoetis Inc. (NYSE: ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging. With UB...
Zoetis Stock: Outlook Remains Muted
Zoetis Inc. (NYSE:ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging.
Zoetis (ZTS): UBS Maintains Neutral Rating, Lowers Price Target to $158 | ZTS Stock News
Zoetis (ZTS): UBS Maintains Neutral Rating, Lowers Price Target to $158 | ZTS Stock News
Zoetis (ZTS) Gains Health Canada Approval for Canine Osteoarthritis Pain Relief
Zoetis (ZTS) Gains Health Canada Approval for Canine Osteoarthritis Pain Relief
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Lenivia approval by Health Canada marks major milestone in the company's continued innovation for canine OA pain.
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment
Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment
Zoetis (ZTS) Awaits EU Approval for Lenivia, an Osteoarthritis Treatment for Dogs
Zoetis (ZTS) Awaits EU Approval for Lenivia, an Osteoarthritis Treatment for Dogs
Zoetis gains EMA panel endorsement for Lenivia for osteoarthritis pain in dogs
Zoetis Receives Positive Opinion from CVMP for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing aut...
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.
Daily Dividend Report: ZTS,DOW,R,PFE,LMT,NWN
The Board of Directors of Zoetis has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Comp...
Zoetis Inc. (ZTS) Announces Fourth Quarter Dividend
Zoetis Inc. (ZTS) Announces Fourth Quarter Dividend
Zoetis (ZTS) Maintains Quarterly Dividend, Sets Payment Date
Zoetis (ZTS) Maintains Quarterly Dividend, Sets Payment Date
Zoetis Declares Fourth Quarter 2025 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will ...
VHT, PFE, BMY, ZTS: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an appro...
Top 50 High-Quality Dividend Growth Stocks For October 2025
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future ...
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
Could Zoetis be the next big opportunity in the pet medicine market? Tune in as our experts break down the company's strengths and weaknesses.
Zoetis: Much Bark, Little Bite - The Stock Remains Pricey
Zoetis Inc. is a global animal health leader with strong fundamentals and a robust innovation pipeline. Click here to read why ZTS stock is a Sell.
Top 15 High-Growth Dividend Stocks For October 2025
The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown ...
Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment
Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment
Zoetis granted conditional approval of Dectomax-CA1 for parasitic infection in cattle
FDA conditionally approves Dectomax-CA1 to treat New World screwworm in cattle. Read more here.
Zoetis Receives Conditional Approval for Dectomax-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
Zoetis Inc. today announced that Dectomax-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention an...
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from ...